organ growth strike back
reiter market outperform rate price target
follow releas result price target appli premium
price-to-earnings multipl ep estim previous
stuck stock post lacklust believ sell-off
overdon anticip sale acceler would materi
admit partli mathemat pleasantli surpris
true organ sale came even better anticip
organ cc revenu growth bounc back compani easili
exceed intern target metric start importantli
surgic product line exit subtract net even
one exclud vsi acquisit technic organ core organ
revenu growth least big uptick deliv
display
also clean quarter ship day impact holiday time
issu real lopsid distributor order signific suppli constraint
full-year constant currenc top-lin guidanc reiter
gm om expect trim bit due mix increment
cost adjust ep bump midpoint due larg
lower tax rate also significantli aid ep
revenu came mln y/i cc line
consensu mln adjust ep y/i versu
consensu
compani segment posit perform across board
vascular na intervent asia oem achiev notabl
improv neotract post anoth quarter strong momentum sale
mln y/i achiev despit temporari suppli issu
suppli back approxim vascular solut similarli continu
show solid momentum put sale mln y/i
compani note growth robust north america emea
updat full-year sale growth guidanc account new fx
expect sit y/i cc unchang
slightli previou rang despit slight tweak revenu
compani rais adjust ep guidanc previous
adjust impli quarterli report top-lin growth
ep organ cc growth like north
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
turn margin perform compani gross margin expand bp y/i
oper margin contract bp y/i lower full-year guidanc
gm expect previous om taken
slightli previous adjust gross margin attribut
unfavor product mix lower margin oem perform better expect tariff relat
china expens relat resolut product engin issu neotract
turn segment perform cc y/i sale growth includ follow vascular na grew
emea grew asia grew oem grew grew
manag also comment urolift continu progress highlight product
subject five real world studi present intern rheolog confer
quarter notabl takeaway studi includ clinic benefit qualiti
life result consist compani studi statist signific
improv symptom prostat smaller gram larger gram urolift
current indic gram men catheter-fre post treatment
also announc call octob urolift approv
market distribut japan
manag updat guidanc keep mani expect adjust rang
due lower foreign exchang environ outlook follow figur highlight key guidanc
metric along select commentari
due less posit outlook foreign currenc environ improv previous revenu organ cc growth unchang last quarter gross reflect unfavor product mix better perform oem lower margin bp y/i bp neotract vascular solutionsoper margin ex bp y/i expect off-set gross margin impact sg partial mitig impact oper due larger tax windfal benefit expect adj abl off-set earn headwind less favor fx environ teleflex incorpor
figur highlight actual vs jmp estim rang revenu metric along select
commentari compani chang report segment therefor previou
estim applic mark na
 edeltacommentsvascular north america bpsintervent north bpsanesthesia north bpssurgic north bpstotal mlnannual bpsgross bp y/i reflect impact vascular soltion neotract acquisit effeci relat footprint consolid program favor price partial off-set unfavor product mix higher manufactur bpsoper bp y/i decreas relat hard prior year comp shortfal gross margin increas level variou synergi plan remain tracktax bpsdown y/i impact tax cut actnet bpsadjust cc driven return distributor order strong growth picc cc primarili result higher sale vascular solut product well growth cc growth driven airway pain manag cc revers neg trend past quarter driven instrument sale initi eas suppli constraint partial off-set exit lower-margin product line continu expect growth rel flat cc larg driven distributor convers emea intervent access expect accler cc led china y/i driven increas volum decid take busi direct last cc higher sale volum exist product time revenu recognit result adopt new account cc primarili due neotract lesser extent latin america busi teleflex incorpor
pure-play med-tech compani transform via merger acquisit number year industri
conglomer foray medic devic industri began late compani began use polym technolog
manufactur intraven cathet tube ultim sold oem grew medic segment late
acquisit rusch pill weck creat medic busi includ dispos
reusabl devic latex cathet endotrach tube laryngoscop face mask tracheotomi tube urolog
gastroenterolog anesthesiolog market well ligat gener surgic devic transform divest
non-med asset make number mostli bolt-on acquisit cap substanti bln purchas
late compani also purchas lma mln vidacar mln
invest thesi valuat subject number risk oper highli competit medic devic market character
price pressur ip disput medic devic highli regul compani fail fda inspect could receiv
warn letter potenti lose abil sell certain product company-specif front reli acquisit bolster
growth profil increas invest guarante acquisit pipelin product accret valu
compani abl execut oper effici program
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign david turkali daniel stauder
